切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2008, Vol. 02 ›› Issue (01) : 32 -35. doi: 10.3877/cma.j.issn.1674-0807.2008.01.010

实验研究

VEGF-C 短发夹RNA 抑制乳腺癌细胞增殖及侵袭能力的实验研究
古立诚1, 肖焕擎2,(), 徐波2, 朱光辉2, 李书华3   
  1. 1.510620 广州,广州市第十二人民医院普外科
    2.510120 广州,广州医学院附属广州市第一人民医院普外科
    3.510182 广州,广州医学院病理教研室
  • 收稿日期:2007-11-01 出版日期:2008-02-01
  • 通信作者: 肖焕擎
  • 基金资助:
    广东省社会发展领域科技计划项目(2006B35530001)

Down-regulation of VEGF-C using short hairpin RNA inhibits proliferation and invasion of human breast cancer cells

Li-cheng GU1, Huan-Qing XIAO,1(), Guang-hui ZHU1, Shu-hua LI1   

  1. 1.Department of General Surgery,Guangzhou Municipal Twelfth People's Hospital,Guangzhou 510620,China
  • Received:2007-11-01 Published:2008-02-01
  • Corresponding author: Huan-Qing XIAO
引用本文:

古立诚, 肖焕擎, 徐波, 朱光辉, 李书华. VEGF-C 短发夹RNA 抑制乳腺癌细胞增殖及侵袭能力的实验研究[J/OL]. 中华乳腺病杂志(电子版), 2008, 02(01): 32-35.

Li-cheng GU, Huan-Qing XIAO, Guang-hui ZHU, Shu-hua LI. Down-regulation of VEGF-C using short hairpin RNA inhibits proliferation and invasion of human breast cancer cells[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2008, 02(01): 32-35.

目的

探讨应用靶向VEGF-C 的短发夹RNA(shRNA)质粒载体在体外抑制乳腺癌细胞株MCF-7 生物学活性的影响。

方法

制备携带有绿色荧光蛋白(GFP)报告基因的VEGF-C-shRNA质粒载体,脂质体转染方法转入乳腺癌细胞株MCF-7,通过倒置荧光显微镜及流式细胞术检测细胞的转染效率,RT-PCR 及Western blot 检测转染细胞内VEGF-C mRNA 及蛋白的表达变化,MTT 法检测细胞增殖抑制率,重组基底膜侵袭实验检测细胞侵袭能力。

结果

高效转染入VEGF-C-shRNA 的MCF-7 细胞VEGF-C mRNA 及蛋白表达水平显著下降;VEGF-C ShRNA 对MCF-7 细胞具有明显的增殖抑制作用,其抑增殖效应呈时间依赖性;VEGF-C-shRNA 可抑制乳腺癌细胞MCF-7 体外侵袭重组基底膜的能力,与阴性shRNA 转染组、空载体组及空白组比较,差异有统计学意义(P<0.05);

结论

VEGF-C在乳腺癌增殖、侵袭转移中发挥重要作用,通过RNA 干扰技术实现VEGF-C 沉默在乳腺癌的基因治疗中具有可行性。

Objective

To investigate the anti-tumor effect of short hairpin RNA (shRNA)-mediated inhibition of VEGF-C (vascular endothelial growth factor C) on human breast cancer in vitro.

Methods

Breast cancer cell line MCF-7 was stably transfected with a VEGF-C short hairpin RNA(shRNA) plasmid vector labeled with green fluorescent protein. The transfected cells were visualized by fluorescent microscope and assayed by flow cytometry. The expression of VEGF-C in transfected cells was determined by RT-PCR and Western blot. The cell growth inhibition rate and the invasive capacity were evaluated by MTT method and reconstituted basement membrane invasion assay.

Results

VEGF-C shRNA specificly and effectively downregulated VEGF-C mRNA and protein expression in vitro. And it also effectively inhibited proliferation and invasive capacity of MCF-7 cells when compared to vehicle,vector and control shRNA.

Conclusions

These data in our study demonstrated that VEGF-C plays an important role in tumor growth,invasive capacity of breast cancer.RNA interference targeting VEGF-C may serve as a potential therapeutic intervention for human breast cancer.

表1 转染shRNA 后不同时点MCF-7细胞的增殖抑制率 (%)
表2 转染shRNA 对乳腺癌MCF-7 细胞侵袭重组基底膜能力的影响
[1]
Akihiko T,Oliver S,Syed A,et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol,2002,9:610-616.
[2]
Tian X,Song S,Wu J,et al.Vascular endothelial growth factor:acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.Biochem Biophys Res Commun,2001,286:505 -512.
[3]
Furudoi A,Tanaka S,Haruma K,et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma.Oncology,2002,62:157 -166.
[4]
Kitadai Y,Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor(VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer,2001,93:662 -666.
[5]
Kaipainen A,Korhoren J,Taipale J,et al.Expression of the fmslike tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA,1995,92:3566 -3570.
[6]
Plate K. From angiogenesis to lymphangiogenesis. Nat Med,2001,7:151 -152.
[7]
Lee A H,Dublin E A,Bobrow L G,et al. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis.J Pathol,1998,185:394 -401.
[8]
Tsurusaki T,Kanda S,Sakai H,et al. Vascular endothelial growth factor C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer,1999,80:309 -313.
[9]
Niki T, Iba S, Tokumou M, et al. Expression of vascular endothelial growth factor A,B,C and D and their relationships to lymph node status in lung adenocarcinoma.Clin Cancer Res,2000,6:2431 -2439.
[10]
Kunath T,Gish G,Lickert H,et al.Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype.Nat Biotechnol,2003,21:559 -561.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[3] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[4] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[5] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[6] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[7] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[8] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[9] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[10] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[11] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[12] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
[15] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 基于自动乳腺超声的列线图模型早期预测HER-2阳性乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华临床医师杂志(电子版), 2024, 18(04): 355-362.
阅读次数
全文


摘要